Autres langues SpringWorks Therapeutics, Inc.

Actions

SWTX

US85205L1070

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 23/04/2024			Varia. 5j.	Varia. 1 janv.
44 ^USD	+2,59 %		+1,38 %	+20,55 %

12/03	Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
07/03	SPRINGWORKS THERAPEUTICS, INC. : JPMorgan Chase toujours positif	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	18/04
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	04/03
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	04/03
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	29/02
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	27/02
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
SpringWorks Therapeutics: Q4 Earnings Snapshot	27/02
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	27/02
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	27/02
SpringWorks Therapeutics to Present at Upcoming Investor Conferences	22/02
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	06/02
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer	02/02
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	31/01
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference	08/01
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	21/12
SpringWorks Therapeutics Closes $316.3 Million Common Stock Public Offering	08/12
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares	08/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues SpringWorks Therapeutics, Inc.

Actions

SWTX

US85205L1070

Autres langues

Filtres